| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004625 | American Journal of Ophthalmology | 2009 | 11 Pages |
Abstract
These results of intravitreal bevacizumab in myopic CNV are very promising with no apparent short-term safety concerns. At 12 months, treated eyes had a significant improvement in visual acuity (VA). OCT findings, as well, showed a trend consistent with the beneficial changes observed for VA. Treatment resulted in complete absence of angiographic leakage in 95% of eyes. Further studies will be needed to better determine long-term efficacy and safety.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Magda Gharbiya, Francesca Allievi, Luigi Mazzeo, Corrado Balacco Gabrieli,